

REFERENCES FOR NPB DIRECTORY – CPD SECTION

Page 84 – 87 PHARMANORD CPD

References:

1. Judy, W. Ubiquinone and ubiquinol. In Proceedings of the Eighth Conference of the International CoQ10 Association, Bologna, Italy, 8–11 October 2015
2. Tomasetti M, Alleva R, Solenghi M, Littarru G. Distribution of antioxidants among blood components and lipoproteins: Significance of lipids/CoQ10ratio as a possible marker of increased risk for atherosclerosis. 2018
3. Mortensen S, Rosenfeldt F, Kumar A, Dolliner P, Filipiak K, Pella D et al. The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure. *JACC: Heart Failure*. 2014;2(6):641-649.
4. Qu H, Meng Y, Chai H, Liang F, Zhang J, Gao Z et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. 2018.
5. Qu H, Guo M, Chai H, Wang W, Gao Z, Shi D. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. *Journal of the American Heart Association*. 2018;7(19)
6. Schmelzer C, Niklowitz P, Okun J, Haas D, Menke T, Döring F. Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. *IUBMB Life*. 2011;63(1):42-48.
7. Safarinejad, M. R. (2009). Efficacy of Coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. *The Journal Of Urology*, 182(1), 237–248
8. Yangying Xu, Victoria Nisenblat, Cuiling Lu, Rong Li, Jie Qiao, Xiumei Zhen and Shuyu Wang. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. *Reproductive Biology and Endocrinology*. 2018;16:29
9. Ben-Meir A, Burstein E, Borrego-Alvarez A, Chong J, Wong E, Yavorska T et al. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging. *Aging Cell*. 2015;14(5):887-895.
10. Cordero M, Cano-García F, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar J. Oxidative Stress Correlates with Headache Symptoms in Fibromyalgia: Coenzyme Q10 Effect on Clinical Improvement. *PLoS ONE*. 2012;7(4):e35677.
11. Maes M. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuroendocrinology letters*. 2009;30(4):470-6.
12. Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T et al. Antifatigue effects of coenzyme Q10 during physical fatigue. *Nutrition*. 2008;24(4):293-299.
13. Liao P, Zhang Y, Liao Y, Zheng NJ, Zhang X (2007) [Effects of coenzymeQ10 supplementation on liver mitochondrial function and aerobic capacity in adolescent athletes]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 23: 491-494.
14. Belardinelli, R., Mucaj, A., Lacalaprice, F., Solenghi, M., Seddaiu, G., Principi, F., Tiano, L., & Littarru, G. P. (2006). Coenzyme Q10 and exercise training in chronic heart failure.

European Heart Journal, 27, 2675–2681

15. Adarsh K, Kaur H, Mohan V. Coenzyme Q10(CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). *BioFactors*. 2008;32(1-4):145-1
 16. Zahedi, H.; Eghtesadi, S.; Seifirad, S.; Rezaee, N.; Shidfar, F.; Heydari, I.; Golestan, B.; Jazayeri, S. Effects of CoQ10 supplementation on lipid profiles and glycemic control in patients with type II diabetes. *J. Diabetes Metabol. Disord*. 2014, 13, 81–89).
 17. Alehagen, U.; Johansson, P.; Björnstedt, M.; Rosén, A.; Dahlström, U. Cardiovascular mortality and N-terminal proBNP reduced after combined selenium and CoQ10 supplementation: A 5 year prospective randomised double blind placebo controlled trial among elderly Swedish citizens. *Int. J. Cardiol*. 2013, 167, 1860–1866.
 18. Alehagen U, Aaseth J, Alexander J, Johansson P. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. *PLOS ONE*. 2018;13(4):e0193120.
 19. López-Lluch, G.; Del Pozo-Cruz, J.; Sánchez-Cuesta, A.; Cortés-Rodríguez, A.B.; Navas, P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. *Nutrition* 2019, 57, 133–140.
-

Page 88 - 91 WEIGHT MANAGEMENT CPD

References:

1. Cornelissen PL et al, 2009, Patterns of subcutaneous fat deposition and the relationship between body mass index and waist-to-hip ratio: implications for models of physical attractiveness, *J Theor Bio*, 256, 3, 343-50
 2. De Laet et al , 2005, Body Mass Index as a predictor of fracture risk: A meta-analysis, *Osteo Int*, 16, 1330-38.
 3. Anton SD et al, 2008, Effects of chromium picolinate on food intake and satiety, *Diabetes Technol Ther*, 10, 5, 405-12
 4. Takaya J et al, 2004, Intracellular magnesium and insulin resistance *Magnes Res*, 17, 2, 126-136
 5. Hruby A, Guasch-Ferre M, 2017, Magnesium Intake, Quality of Carbohydrates, and Risk of Type 2 Diabetes: Results From Three U.S. Cohorts. *Diabetes Care*, 40, 12, 1695-1702
 6. Mooren F, 2015, Magnesium and disturbances in carbohydrate metabolism. *Diabetes Obes Metab*, 17, 9, 813-823
 7. Payahoo L et al, 2013, Effects of zinc supplementation on the anthropometric measurements, lipid profiles and fasting blood glucose in the healthy obese adults. *Adv Pharm Bull*, 3, 1, 161-5
 8. Raygan F, Rezavandi Z, 2016, The effects of coenzyme Q10 administration on glucose homeostasis parameters, lipid profiles, biomarkers of inflammation and oxidative stress in patients with metabolic syndrome. *Eur J Nutr*, 55, 8, 2357-236
 9. Sigal RJ et al, 2007, Effects of aerobic training, resistance training or both on glycemic control in type 2 diabetes: a randomised trial, *Ann Intern Med*, 147, 6, 357-69
-

Page 92 -94 – Controlling Cholesterol CPD

References

1. High cholesterol [Internet]. nhs.uk. 2018 [cited 16 November 2018]. Available from: <https://www.nhs.uk/conditions/high-cholesterol/>

2. Hans-Willi P. Low Density Lipoprotein Cholesterol and Coronary Heart Disease – Lower is Better. *European Cardiology Review*. 2005;1(1):18.
3. Enger S, Herbjørnsen K, Erikssen J, Fretland A. High density lipoproteins (HDL) and physical activity: the influence of physical exercise, age and smoking on HDL-cholesterol and the HDL-/total cholesterol ratio. *Scandinavian Journal of Clinical and Laboratory Investigation*. 1977;37(3):251-255.
4. Catalina-Romero C, Calvo E, Sánchez-Chaparro M, Valdivielso P, Sainz J, Cabrera M et al. The relationship between job stress and dyslipidemia. *Scandinavian Journal of Public Health*. 2013;41(2):142-149.
5. Treatment [Internet]. nhs.uk. 2018 [cited 16 November 2018]. Available from: <https://www.nhs.uk/conditions/high-cholesterol/treatment/>
6. Qu H, Meng Y, Chai H, Liang F, Zhang J, Gao Z et al. The effect of statin treatment on circulating coenzyme Q10 concentrations: an updated meta-analysis of randomized controlled trials. 2018.
7. Qu H, Guo M, Chai H, Wang W, Gao Z, Shi D. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. *Journal of the American Heart Association*. 2018;7(19).
8. Mortensen S, Rosenfeldt F, Kumar A, Dolliner P, Filipiak K, Pella D et al. The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure. *JACC: Heart Failure*. 2014;2(6):641-649.
9. Singh Rb, Neki NS, Kartikey et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. *Molecular cellular biochemistry* 2003; 246:75-82
10. Schmelzer C, Niklowitz P, Okun J, Haas D, Menke T, Döring F. Ubiquinol-induced gene expression signatures are translated into altered parameters of erythropoiesis and reduced low density lipoprotein cholesterol levels in humans. *IUBMB Life*. 2011;63(1):42-48.
11. Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal*. 2011;9(7).
12. Halbert SC e. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. - PubMed - NCBI [Internet]. ncbi.nlm.nih.gov. 2018 [cited 16 November 2018]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20102918>
13. Abdelbaset M, Safar M, Mahmoud S, Negm S, Agha A. Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. *Canadian Journal of Physiology and Pharmacology*. 2014;92(6):481-489.
14. Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. *Nutrition Reviews*. 2013;71(5):282-299.
15. Kwak J, Kim J, Paek J, Lee Y, Kim H, Park D et al. Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials. *Nutrition Research and Practice*. 2014;8(6):644.
16. Wei M, Jacobson T. Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. *Current Atherosclerosis Reports*. 2011;13(6):474-483.
17. Scientific Opinion on the substantiation of health claims related to alpha linolenic acid (ALA) and brain and neurological development (ID 491), molecule precursors

regulating cell functions (ID 492, 4671), maintenance of normal cardiac function (ID 509. EFSA Journal. 2011;9(4):2050.

18. Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA Journal. 2010;8(12).
-

Page 96 - 99 – Medicated Malnutrition

References

1. Boullata JI, Barber JR. A perspective on drug-nutrient interactions. In: Boullata JI, Armenti VA, eds. Handbook of drug-nutrient 47.
2. Chan L-N. Drug-nutrient interaction in clinical nutrition. *Curr Opin Clin Nutr Metab Care* 2002;5:327–332.
3. Dubick MA. Interactions of vitamin B6 and xenobiotics. In: Hathcock JN, ed. *Nutritional Toxicology*, Vol. III. Academic Press, New York, NY, 1989, pp. 97–121.
4. Bartel PR, Ubbink JB, Delport R, et al. Vitamin B-6 supplementation and theophylline-related effects in humans. *Am J Clin Nutr* 1994;60:93–99.
5. McLean AEM. Drug nutrient interactions from experiment to epidemiology. In: *Nutrition in health and disease and international development*, Symp XII Internat Congr. Alan R. Liss, New York, NY, 1981, pp. 729–737
6. Bailey LB, Duhaney RL, Maneval DR, et al. Vitamin B-12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. *J Nutr* 2002;132:1872–1878.
7. McNulty H, McKinley MC, Wilson B, et al. Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements. *Am J Clin Nutr* 2002;76:436–441.
8. Fleming BJ, Genuth SM, Gould AB, et al. Laxative-induced hypokalemia, sodium depletion, and hyperreninemia. *Ann Intern Med* 1975;83:60–62.
9. Thorn GW. Clinical considerations in the use of corticosteroids. *N Engl J Med* 1966;274:775–781.
10. Luzecky MH, Burman KD, Schultz ER. The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration. *S Med J* 1974;67:495–497.
11. Movig KLL, Leufkens HGM, Lenderink AW, Egberts ACG. Serotonergic antidepressants associated with an increased risk for hyponatremia in the elderly. *Eur J Clin Pharmacol* 2002;58:143–148.

12. Stedman CA, Begg EK, Kennedy MA, et al. Cytochrome P450 2D6 genotype does not predict SSRI induced hyponatraemia. *Human Psychopharmacol* 2002;17:187–190.
13. Subbiah V, Tayek JA. Tetany secondary to the use of a proton-pump inhibitor. *Ann Intern Med* 2002;137:219–220.
14. Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, Seidell JC, Lips P. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. *The Journal of Clinical Endocrinology & Metabolism*. 2005 Jul 1;90(7):4119-23.
15. Huffman GB. Evaluating and treating unintentional weight loss in the elderly. *Am Fam Physician* 2002;65:640–650.
16. Markley EJ, Mattes-Kulig DA, Henkin RI. A classification of dysgeusia. *J Am Diet Assoc* 1998;83:578–580.
17. Taylor AT. Nausea and vomiting. In: DiPiro JT, ed. *Pharmacotherapy: A Pathophysiologic Approach*, ed 5. McGraw-Hill, New York, 2002, pp. 641–653.
18. Gorbach SL, Bengt E, Gustafsson memorial lecture. Function of the normal human microflora. *Scand J Infect Dis Suppl* 1986;49:17-30
19. Hill MJ. Intestinal flora and endogenous vitamin synthesis. *Eur J Cancer Prev* 1997;6:S43-5
20. Recker RR. Calcium absorption and achlorhydria. *N Engl J Med* 1985;313:70-3
21. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. *J Clin Invest* 1984;73:640-7
22. Safety Alert. Proton Pump Inhibitor drugs (PPIs): Drug Safety Communication - Low Magnesium Levels Can Be Associated With Long-Term Use. U.S. Food and Drug Administration, March 2, 2011.
23. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. *Neth J Med* 2009;67:169-72
24. Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. *Am Heart J* 2001;142:E2
25. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. *Clin Pharmacol Ther* 1995;57:62-6
26. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889-92.
27. Carpentier JL, Bury J, Luyckx A, et al. Vitamin B12 and folic acid serum levels in diabetics under various therapeutic regimens. *Diabete Metab* 1976;2:187-90
28. Callaghan TS, Hadden DR, Tomkin GH. Megaloblastic anemia due to vitamin B12 malabsorption associated with longterm metformin treatment. *Br Med J* 1980;280:1214-5.
29. Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. *J Am Diet Assoc* 1991;91:66-73.

30. Garabedian-Ruffalo SM, Ruffalo RL. Drug and nutrient interactions. *Am Fam Physician* 1986;33:165-74
31. Brady JA, Rock CL, Horneffer MR. Thiamin status, diuretic medications, and the management of congestive heart failure. *J Am Diet Assoc* 1995;95:541-4
32. Pfitzenmeyer P, Guillard JC, d'Athis P, et al. Thiamine status of elderly patients with cardiac failure including the effects of supplementattion. *Int J Vitam Nutr Res* 1994;64:113-8
33. Krause KH, Berlit P, Bonjour JP. Impaired biotin status in anticonvulsant therapy. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society.* 1982 Nov;12(5):485-6.
34. Millennium Pharmaceuticals, Inc. Velcade for injection (bortezomib) prescribing information. Cambridge, MA; 2003. Available from <http://www.fda.gov/cder/foi/label/2003/021602lbl.pdf>. Accessed January 10, 2005
35. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. *Cancer Control* 2003;10:361-9.
36. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. *JAMA* 2003;290:2149-58.
37. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. *J Clin Oncol* 2002;20: 2240-50.
38. Wakeman M.P. Development of an evidence based, interactive database to quantitatively assess the impact of medication on the nutrient status of patients pre- and post-bariatric surgery *OBES SURG* (2019) 29 (Suppl 1):S7
39. Wakeman M. An Interactive Database to Quantitatively Assess the Impact of Medication on Nutrient Status. *IJSNEM* 2019, 29, SI 1, 12-13